Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
5837 5774 5697 5665 5518 Last
1167600 1299700 995100 1234200 1387000 Volume
+1.62% -1.08% -1.33% -0.56% -2.59% Change
Financials
Sales 2021 306 B 2 772 M 2 772 M
Net income 2021 114 B 1 033 M 1 033 M
Net cash position 2021 348 B 3 147 M 3 147 M
P/E ratio 2021 14,6x
Yield 2021 1,96%
Sales 2022 296 B 2 680 M 2 680 M
Net income 2022 101 B 915 M 915 M
Net cash position 2022 365 B 3 299 M 3 299 M
P/E ratio 2022 16,3x
Yield 2022 2,00%
Capitalization 1 710 B 15 521 M 15 477 M
EV / Sales 2021 4,45x
EV / Sales 2022 4,55x
Nbr of Employees 5 222
Free-Float 87,9%
More Financials
Company
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant... 
Read more
Sector
Pharmaceuticals
Calendar
08/02Earnings Release
More about the company
Ratings of Shionogi & Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about SHIONOGI & CO., LTD.
04:33aSHIONOGI  : Notice of Disposal of Treasury Shares as Restricted Stock Compensati..
PU
04:30aHALOZYME THERAPEUTICS  : and ViiV Healthcare Agree to License Deal on Drug Deliv..
MT
02:33aGLAXOSMITHKLINE  : GSK's ViiV Healthcare Enters License Deal For Halozyme's Drug..
MT
12:31aGlaxoSmithKline Says ViiV, Halozyme Signed Deal for Drug-Delivery Technology
DJ
06/17Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zu..
AQ
06/09Japanese shares rise, Eisai drops after 2 days of limit-up gains
RE
06/08Th2 Chemokine TARC Kit 'HISCL TARC Assay Kit' is Approved for an Additional I..
AQ
06/07SHIONOGI  : Sign a MoU with World Anti-Doping Agency (WADA) to Prevent Misuse an..
AQ
05/31SHIONOGI  : Announces Corporate Reorganization and Personnel Reassignment
AQ
05/24SHIONOGI  : Announces Novel Coronavirus Antigen test agent 'LumiraDx SARS-CoV-2 ..
AQ
05/10Japanese shares tumble on tech sell-off, pandemic woes
RE
05/10JAPAN'S SHIONOGI MAY ROLL OUT COVID : Kyodo
RE
05/10URGENT : Japan's Shionogi says looking to provide COVID-19 vaccine this year
AQ
05/10SHIONOGI  : Financial results for the year ended March 31, 2021
PU
05/06SHIONOGI  : Judgment of the Complaint for the Rescission of Tax Reassessment by ..
PU
More news
News in other languages on SHIONOGI & CO., LTD.
05:34aSHIONOGI  : le Japon mise sur la pharma pour produire son propre vaccin
04:57aPLANÈTE BOURSE  : La revue de presse du mardi 22 juin 2021
06/10MÄRKTE ASIEN/Etwas freundlicher - Sydney mit neuem Rekordhoch
05/10Tokyo effarouchée par la chute du Nasdaq
03/23TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in calo, pesano titoli cinesi e rendim..
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Chart SHIONOGI & CO., LTD.
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 6 466,67 JPY
Last Close Price 5 518,00 JPY
Spread / Highest target 45,0%
Spread / Average Target 17,2%
Spread / Lowest Target -3,95%
EPS Revisions
Managers and Directors
NameTitle
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Teppei Mogi Independent Outside Director
Keiichi Ando Independent Outside Director
Hiroshi Ozaki Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIONOGI & CO., LTD.0.53%15 097
JOHNSON & JOHNSON4.10%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639